全文获取类型
收费全文 | 758篇 |
免费 | 61篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 9篇 |
妇产科学 | 1篇 |
基础医学 | 161篇 |
口腔科学 | 1篇 |
临床医学 | 39篇 |
内科学 | 400篇 |
外科学 | 145篇 |
综合类 | 2篇 |
药学 | 4篇 |
肿瘤学 | 56篇 |
出版年
2019年 | 2篇 |
2018年 | 4篇 |
2015年 | 3篇 |
2014年 | 2篇 |
2013年 | 4篇 |
2012年 | 12篇 |
2011年 | 18篇 |
2010年 | 6篇 |
2009年 | 5篇 |
2008年 | 9篇 |
2007年 | 22篇 |
2006年 | 25篇 |
2005年 | 31篇 |
2004年 | 23篇 |
2003年 | 41篇 |
2002年 | 32篇 |
2001年 | 37篇 |
2000年 | 24篇 |
1999年 | 22篇 |
1998年 | 17篇 |
1997年 | 12篇 |
1996年 | 19篇 |
1995年 | 10篇 |
1994年 | 12篇 |
1993年 | 5篇 |
1992年 | 20篇 |
1991年 | 18篇 |
1990年 | 22篇 |
1989年 | 23篇 |
1988年 | 34篇 |
1987年 | 27篇 |
1986年 | 29篇 |
1985年 | 22篇 |
1984年 | 27篇 |
1983年 | 21篇 |
1982年 | 23篇 |
1981年 | 13篇 |
1980年 | 7篇 |
1979年 | 24篇 |
1978年 | 21篇 |
1977年 | 18篇 |
1976年 | 14篇 |
1975年 | 8篇 |
1974年 | 15篇 |
1973年 | 13篇 |
1972年 | 6篇 |
1971年 | 2篇 |
1970年 | 4篇 |
1969年 | 4篇 |
1968年 | 3篇 |
排序方式: 共有819条查询结果,搜索用时 15 毫秒
1.
Brenda M Sandmaier Storb Rainer Yanfang Liu Erlinda B Santos Eileen Bryant Friedrich G Schuening H Joachim Deeg Kristy Seidel Theodore Graham 《Transplant immunology》1996,4(4):271-274
920 cGy total body irradiation (TBI) is adequate for consistently successful engraftment of marrow from dog leukocyte antigen (DLA)-identical littermates; however, the dose is inadequate to ensure a marrow graft from DLA-nonidentical unrelated donors. Such mismatched grafts are successful only after 1800 cGy, given in three fractions. While anti-T-cell reagents enhance engraftment of DLA-identical littermate marrow after 920 cGy, they fail to be effective in the DLA-nonidentical setting. However, a monoclonal antibody (mAb) to CD44, S5, was found to be very effective in enhancing engraftment of DLA-nonidentical marrow. The current study asked whether mAb S5 was also effective in the setting of DLA-identical littermate transplants. To this purpose, the TBI dose was lowered to 450 cGy, a dose after which 70% of such grafts failed. Four dogs were treated with antibody S5, 0.2 mg/kg on days −7 though −2 (per previously published protocol), given 450 cGy TBI followed by marrow grafts from their DLA-identical littermates. All four dogs rejected their grafts; two of these died from marrow aplasia, and two survived with endogenous marrow recovery. This result was not statistically significantly different from that in 17, historical (n = 5) and concurrent (n = 12), control dogs where 11 of 17 animals rejected. Even if ten experimental animals were transplanted and all six remaining dogs engrafted, the results still would not have been significantly different from control. This result is in contrast to the successful engraftment promoted by pretreatment with antibody S5 of DLA-nonidentical unrelated dogs, consistent with the notion that different host cells are involved in graft rejection in the two disparate histocompatibility settings. 相似文献
2.
3.
4.
Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. 总被引:2,自引:0,他引:2
C Anasetti P J Martin R Storb F R Appelbaum P G Beatty J Davis K Doney H F Hill P Stewart K M Sullivan 《Transplantation》1992,54(5):844-851
Treatment with the monoclonal antibody OKT3 specific for the CD3 complex associated with the T cell antigen receptor can reverse acute rejection of human renal allografts. However, efficacy of anti-CD3 antibodies for treatment of patients with acute graft-versus-host disease after marrow transplantation has not been established. The dose-limiting side effects resulting from T cell activation induced by some anti-CD3 antibodies in vivo have discouraged their use for this application. We now report a phase I-II study of GVHD treatment with the anti-CD3 antibody BC3, a monoclonal murine IgG2b that, unlike OKT3, does not activate T cells. Fourteen patients were treated with BC3 after progression of acute GVHD despite treatment with cyclosporine and corticosteroids, and three patients received BC3 as primary treatment for GVHD. BC3 was administered at a dose of 0.1 or 0.2 mg/kg/day for seven or eight days. Five patients achieved complete resolution of GVHD, eight patients had partial improvement, two patients had no change, and two patients had progression of GVHD on therapy. Responses were sustained in 8 of 13 patients. Mild chills, fever, hypertension, and chest discomfort occurred in various combinations following 6 of 17 (35%) initial infusions of BC3 and following 4 of 99 (4%) subsequent infusions. In each instance it was possible to continue BC3 therapy without adjusting the dose or treatment schedule. In each patient treated, the absolute count of peripheral blood lymphocytes decreased transiently but returned to baseline within 22 hr after the first infusion. Circulating T cells had surface CD3 molecules saturated by the infused antibody in all but one patient. Four patients survived longer than one year after treatment with antibody BC3, and 13 patients died of infection or organ failure. Administration of the nonmitogenic anti-CD3 antibody BC3 was associated with improvement in the clinical manifestations of GVHD with minimal acute toxicity. Efficacy of antibody treatment did not depend on depletion of circulating T cells. Therefore, antibody BC3 may be achieving therapeutic immunosuppression by modulating T cell function. Controlled studies in patients treated earlier in the course of GVHD should determine whether antibody BC3 can improve survival. 相似文献
5.
Abstract: Partial-length cDNA clones and full-length genomic clones corresponding to a complete canine DQB class It gene were isolated. Southern analyses suggested the presence of two DQB genes - one of which appeared to be a pseudogene lacking exon 2 called DQB2. The other DQB gene, called DQB1, was isolated from a genomic phage clone and contained six exons. The DQB1 clone was restriction mapped, and exon 2 was sequenced from 70 dogs. Twenty alleles were found. Most of the amino acid substitutions occurred at putative positions in the peptide binding site. Inheritance of these sequences showed Mendelian segregation with one or two alleles per dog. Cluster analysis of the nucleotide and predicted amino acid sequences subdivided the canine DQB1 alleles into four major allelic groups. The number of nonsynonymous changes was higher than the number of synonymous changes in the putative antigen recognition sites suggestive of positive selection. 相似文献
6.
Polymorphism analysis of four canine MHC class I genes 总被引:1,自引:0,他引:1
Abstract: We have studied the variability of four structurally complete dog leukocyte antigen (DLA) class I genes, termed DLA-12, -88, -79 and -64, in a population of mixed breed, unrelated dogs. The human HLA and canine DLA loci share a high degree of similarity in terms of gene structure. This analysis focused on the first three exons of each of four complete canine genes. Exons two and three are the major source of polymorphism in the corresponding human genes. In this analysis, DLA-88 was found to be significantly more polymorphic than the other three genes, with 44 distinct alleles observed among 63 mixed breed, unrelated dogs. The remaining genes had between one and four alleles when examined in 25 dogs. This work was carried out as part of an effort to develop an MHC typing system for the dog, which is critical to the further development of preclinical studies of hematopoietic stem cell and solid organ transplantation in the canine model. 相似文献
7.
Kim Robien Jeannette Bigler Yutaka Yasui John D Potter Paul Martin Rainer Storb Cornelia M Ulrich 《Biology of blood and marrow transplantation》2006,12(9):973-980
Methylenetetrahydrofolate reductase (MTHFR) and thymidylate synthase (TS) play key roles in intracellular folate metabolism. Polymorphisms in these enzymes have been shown to modify toxicity of methotrexate (MTX) after hematopoietic cell transplantation. In this study, we evaluated the risk of acute graft-versus-host disease (GVHD) associated with genetic variation in recipient and donor MTHFR and TS genotypes to assess whether genotype alters the efficacy of MTX in acute GVHD prophylaxis. Data on the transplantation course were abstracted from medical records for 304 adults who received allogeneic hematopoietic cell transplants. MTHFR (C677T and A1298C) and TS (enhancer-region 28-base pair repeat, TSER, and 1494del6) genotypes were determined using polymerase chain reaction/restriction fragment length polymorphism and TaqMan assays. Multivariable logistic regression was used to assess the associations between genotypes and risk of acute GVHD. Compared with recipients with the wild-type MTHFR 677CC genotype, those with the variant 677T allele showed a decreased risk of detectable acute GVHD (677CT: odds ratio, 0.8; 95% confidence interval, 0.4-1.6; 677TT: odds ratio, 0.4; 95% confidence interval, 0.2-0.8; P for trend = .01). The variant MTHFR 1298C allele in recipients was associated with an increased risk of acute GVHD compared with the wild-type MTHFR 1298AA genotype (1298AC: odds ratio, 2.0; 95% confidence interval, 1.1-3.9; 1298CC: odds ratio, 3.6; 95% confidence interval, 1.0-12.7; P for trend < .01). No association with risk of acute GVHD was observed for donor MTHFR genotypes or for recipient or donor TS genotypes, with the exception of an increase in acute GVHD among recipients whose donors had the TSER 3R/2R genotype (odds ratio, 3.0; 95% confidence interval, 1.3-7.2). These findings indicate that host, but not donor, MTHFR genotypes modify the risk of acute GVHD in recipients receiving MTX, in a manner consistent with our previously reported associations between MTHFR genotypes and MTX toxicity. A direct trade-off between drug toxicity and drug efficacy may play a role. Alternatively, the systemic folate environment, regulated by host tissues, might influence donor T-cell growth and activity. 相似文献
8.
Originally, allogeneic hematopoietic stem cell transplantation (HSCT) was viewed as a form of rescue from the marrow lethal
effects of high doses of chemo-radiotherapy used to both eradicate malignancy and to provide sufficient immunosuppression
to ensure allogeneic engraftment. Clear evience of a therapeutic graft-versus-tumor (GVT) effect mediated by allogeneic affector
cells (T cells) has prompted the exploration of HSCT regimens that rely solely upon host immunosuppression (non-myeloblative)
to facilitate allogenic donor engraftment. The engrafted donor effector cells are then used to accomplish the task of eradicating
host malignant cells. The non-myeloblative regimen developed in Seattle uses 2 Gy total body irradiation (TBI) before transplant
followed by postgrafting cyclosporine (CSP) and mycophenolate mofetil (MMF). This regimen resulted in initial mixed donor-host
chimerism in all patients with hematologic malignancies and genetic disorders who received HLA-matched sibling allografts.
The 17% incidence of graft rejection was reduced to 3% with the addition of fludarabine, 30 mg/m2/day on d-4,-3, and-2. The non-myeloblative combination of fludarabine/TBI has also been successful at achieving high engraftment
rates in recipients of 10 of 10 HLA antigen matched unrelated donor HSCTs in patients with hematologic malignancies. By reducing
acute toxicities relative to conventional HSCT, most patients have received their pre- and post-HSCT therapy almost exclusively
as outpatients. Acute and chronic GVHD occur after non-myeloablative HSCT, but the incidence and severity appear less compared
to conventional HSCT. As in conventional transplants, immune dysregulation from GVHD and its treatment and delayed reconstitution
of immune function continue to present risks to patients who have otherwise undergone successful non-myeloablative HSCT. Cellular
therapeutic effects have been nobserved after non-myeloblative HSCT such as correction of inherited genetic disorders, and
eradication of hematologic malignant diseases and renal cell carcinoma via GVT responses. 相似文献
9.
Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms 总被引:11,自引:0,他引:11
K M Sullivan R Storb C D Buckner A Fefer L Fisher P L Weiden R P Witherspoon F R Appelbaum M Banaji J Hansen 《The New England journal of medicine》1989,320(13):828-834
The occurrence of graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation for leukemia is thought to decrease the probability of recurrence. To study this effect (called adoptive immunotherapy) we modified the prophylaxis of GVHD in patients with advanced hematologic neoplasms (mostly leukemia) who received bone marrow transplants. Patients under 30 years of age were randomly assigned to one of three regimens of post-transplantation immunosuppression: Group I (n = 44) received a standard course of methotrexate for 102 days after transplantation, Group II (n = 40) received an abbreviated (11-day) course of methotrexate, and Group III (n = 25) received the standard course of methotrexate plus viable buffy-coat cells from the marrow donors. All 109 patients received cyclophosphamide (60 mg per kilogram of body weight on each of two days), total-body irradiation (2.25 Gy daily for seven days), and unmodified marrow from HLA-identical sibling donors. The frequency of GVHD of Grades II through IV was 25 percent in Group I, 59 percent in Group II, and 82 percent in Group III (P = 0.0001). The incidence of chronic GVHD, however, did not differ significantly among the groups (33, 51, and 44 percent, respectively), nor did the five-year probability of recurrence of disease (38, 45, and 33 percent, respectively). However, mortality from causes other than cancer was 34 percent in Group I, 45 percent in Group II, and 64 percent in Group III (I vs. III, P = 0.024); the deaths were due primarily to infections complicating the course of GVHD. With a median follow-up of 5.1 years (range, 3.9 to 7.4), disease-free survival was 41 percent in Group I, 30 percent in Group II, and 24 percent in Group III (the differences were not statistically significant). We conclude that abbreviating methotrexate prophylaxis or infusing donor buffy-coat cells increased the incidence of acute GVHD and related mortality without altering the incidence of chronic GVHD or the recurrence of malignant disease. 相似文献
10.
Mice with the scid mutation have a defect in the V(D)J recombinase. In order to
determine whether the SCID product is normally present in mature B cells that do not
have the recombinase activity, scid pre-B cells were fused with myeloma cells. It was
found that in the hybrid cells, a rearrangement test gene was correctly joined
immediately after fusion. The same test gene was aberrantly rearranged in the scid pre-B
cells. Stable hybrids between the scid pre-B and the myeloma cells had lost the
expression of RAG-1 and RAG-2 genes, supporting the previous finding of an inhibitor
of rearrangement in myeloma cells that acts shortly after fusion. Thus, mature B cells
apparently contain the SCID product, the wild type SCID function is not competitively
interfered with by products present in scid pre-B cells, and the SCID product seems not
to be a target for the recombinase inhibitor. 相似文献